| 2022-06-08 | -55.7% | legal | SEC EDGAR | RIGL 8-K: 8.01 and (SEC Filing) |
| 2024-11-07 | +45.1% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2022-12-02 | +41.6% | legal | SEC EDGAR | RIGL 8-K: 8.01 and (SEC Filing) |
| 2022-12-02 | +41.6% | legal | AskTraders | Rigel Pharma (RIGL) Stock Soared 40% as FDA Approves New Drug - AskTraders |
| 2025-08-05 | +31.2% | earnings | Seeking Alpha | Rigel Pharmaceuticals GAAP EPS of $3.28 beats by $1.67, revenue of $101.68M beats by $29.1M |
| 2025-08-05 | +31.2% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2023-01-09 | +28.2% | legal | SEC EDGAR | RIGL 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-11-05 | +28.0% | earnings | Seeking Alpha | Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats |
| 2025-11-05 | +28.0% | earnings | Seeking Alpha | Rigel raises 2025 revenue guidance to $285M–$290M as commercial sales growth accelerates |
| 2025-11-05 | +28.0% | earnings | Seeking Alpha | Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript |
| 2022-10-11 | -26.2% | legal | SEC EDGAR | RIGL 8-K: 2.05, 5.02, 8.01 (SEC Filing) |
| 2025-08-06 | +24.9% | earnings | Seeking Alpha | Rigel Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-06 | +24.9% | earnings | Seeking Alpha | Rigel targets up to $280M 2025 revenue as IRA boosts sales and pipeline advances |
| 2025-08-06 | +24.9% | earnings | Seeking Alpha | Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript |
| 2025-11-04 | +24.3% | earnings | Seeking Alpha | Rigel Pharmaceuticals GAAP EPS of $1.46 beats by $0.56, revenue of $69.46M beats by $7.58M |
| 2025-11-04 | +24.3% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2025-11-04 | +24.3% | earnings | Yahoo Finance | Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance |
| 2022-03-01 | +20.8% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2022-06-23 | -20.6% | legal | SEC EDGAR | RIGL 8-K: 8.01 (SEC Filing) |
| 2023-03-07 | +19.1% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2024-05-07 | -19.0% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2024-12-09 | -18.4% | legal | SEC EDGAR | RIGL 8-K: 8.01 and (SEC Filing) |
| 2024-06-25 | -18.2% | legal | SEC EDGAR | RIGL 8-K: 8.01 and (SEC Filing) |
| 2024-02-22 | +15.7% | legal | SEC EDGAR | RIGL 8-K: 1.01 and 2.01 (SEC Filing) |
| 2022-08-02 | +15.6% | legal | SEC EDGAR | RIGL 8-K: 1.01, 2.02, 2.03 (SEC Filing) |
| 2025-11-11 | +15.3% | earnings | Yahoo Finance | Rigel Pharmaceuticals (RIGL) Is Up 21.7% After Strong Q3 Results and Raised 2025 Guidance - Yahoo Finance |
| 2026-03-03 | -14.2% | earnings | Motley Fool | Rigel Pharma (RIGL) Earnings Call Transcript |
| 2026-03-03 | -14.2% | earnings | MarketBeat | Rigel Pharmaceuticals Q4 Earnings Call Highlights |
| 2026-03-03 | -14.2% | earnings | Seeking Alpha | Rigel Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-03-03 | -14.2% | earnings | Seeking Alpha | Rigel Pharmaceuticals GAAP EPS of $13.54 beats by $12.31, revenue of $69.8M beats by $1.1M |
| 2026-03-03 | -14.2% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2026-03-03 | -14.2% | earnings | Yahoo Finance | Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates - Yahoo Finance |
| 2026-01-08 | -13.8% | news | simplywall.st | Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt? - simplywall.st |
| 2021-08-13 | -12.3% | legal | SEC EDGAR | RIGL 8-K: 8.01 and (SEC Filing) |
| 2024-08-06 | +11.9% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2021-12-17 | +11.9% | legal | SEC EDGAR | RIGL 8-K: 5.02 (SEC Filing) |
| 2026-03-04 | -10.7% | earnings | GuruFocus.com | Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and ... |
| 2026-03-04 | -10.7% | news | Simply Wall St. | How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress |
| 2026-03-04 | -10.7% | earnings | Seeking Alpha | Rigel Pharma slides as falling contract revenue to drive contraction |
| 2026-03-04 | -10.7% | earnings | Seeking Alpha | Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript |
| 2026-03-04 | -10.7% | news | Seeking Alpha | Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ) - Seeking Alpha |
| 2025-08-04 | +9.6% | earnings | Seeking Alpha | Rigel Pharmaceuticals Q2 2025 Earnings Preview |
| 2025-08-13 | +9.4% | earnings | Seeking Alpha | Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout - Seeking Alpha |
| 2025-03-04 | -9.2% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2025-11-03 | -9.1% | earnings | Seeking Alpha | Rigel Pharmaceuticals Q3 2025 Earnings Preview |
| 2025-11-03 | -9.1% | earnings | Yahoo Finance | Rigel Pharmaceuticals Inc (RIGL) Q3 2025 Earnings Report Preview: What to Expect - Yahoo Finance |
| 2022-05-23 | -9.1% | legal | SEC EDGAR | RIGL 8-K: 5.02 and 5.07 (SEC Filing) |
| 2025-08-14 | +8.2% | earnings | Seeking Alpha | Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout |
| 2021-08-03 | -7.5% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | -7.0% | legal | SEC EDGAR | RIGL 8-K: 2.02, 8.01 (SEC Filing) |
| 2024-03-05 | +6.6% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2023-05-30 | +6.6% | legal | SEC EDGAR | RIGL 8-K: 5.02 and 5.07 (SEC Filing) |
| 2026-04-21 | -6.6% | expansion | Seeking Alpha | Eli Lilly terminates license agreement with Rigel over ocadusertib |
| 2022-01-28 | +6.5% | legal | SEC EDGAR | RIGL 8-K: 5.02 and (SEC Filing) |
| 2026-04-07 | +6.1% | news | PR Newswire | Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 2021-05-05 | -6.1% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2025-11-07 | -6.0% | earnings | Seeking Alpha | Rigel Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2023-11-07 | +5.6% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2025-09-25 | -5.6% | news | Seeking Alpha | Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion (NASDAQ:RIGL) - Seeking Alpha |
| 2025-09-25 | -5.6% | news | simplywall.st | Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount? - simplywall.st |
| 2025-12-20 | +5.6% | news | Trefis | How Low Can Rigel Pharmaceuticals Stock Really Go? - Trefis |
| 2026-04-22 | -5.5% | earnings | MarketBeat | Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Down 5.1% - Time to Sell? - MarketBeat |
| 2022-07-25 | +5.4% | legal | SEC EDGAR | RIGL 8-K: 8.01 (SEC Filing) |
| 2022-11-03 | +5.3% | legal | SEC EDGAR | RIGL 8-K: 1.01, 2.02, 5.03 (SEC Filing) |
| 2026-01-27 | -5.1% | news | Seeking Alpha | Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 |
| 2023-08-01 | -4.8% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2026-01-15 | -4.4% | news | Seeking Alpha | Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-03-02 | -4.1% | earnings | Seeking Alpha | Rigel Pharmaceuticals Q4 2025 Earnings Preview |
| 2025-10-08 | -4.0% | news | ChartMill | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Stands Out as a Top Growth Stock Candidate - ChartMill |
| 2024-04-12 | -3.9% | legal | SEC EDGAR | RIGL 8-K: 1.01 (SEC Filing) |
| 2022-05-03 | +3.8% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2025-03-27 | -3.5% | legal | SEC EDGAR | RIGL 8-K: 8.01 and (SEC Filing) |
| 2026-03-31 | +3.2% | news | PR Newswire | Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology |
| 2025-05-06 | -2.9% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2021-11-02 | -2.7% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2026-01-21 | +2.7% | news | ChartMill | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A GARP Stock with Affordable Growth and Strong Fundamentals - ChartMill |
| 2026-03-10 | -2.6% | news | Seeking Alpha | Rigel Pharmaceuticals: Growing Where It Matters |
| 2026-02-27 | -2.6% | news | TradingView | Implied Volatility Surging for Rigel Pharmaceuticals Stock Options - TradingView |
| 2026-01-01 | -2.5% | news | Seeking Alpha | Rigel Pharma: Formulating A Game Plan For 2026 |
| 2024-05-29 | +2.4% | legal | SEC EDGAR | RIGL 8-K: 5.02 and 5.07 (SEC Filing) |
| 2025-01-13 | +2.4% | legal | SEC EDGAR | RIGL 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-05-07 | +2.4% | earnings | Seeking Alpha | Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum |
| 2025-05-07 | +2.4% | earnings | Seeking Alpha | Rigel Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2025-05-07 | +2.4% | earnings | Seeking Alpha | Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance |
| 2022-02-17 | -2.3% | legal | SEC EDGAR | RIGL 8-K: 1.01 and 2.03 (SEC Filing) |
| 2026-04-09 | -2.3% | earnings | Seeking Alpha | Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade) |
| 2026-01-05 | +2.2% | earnings | Yahoo Finance | Why Analysts Say The Rigel Pharmaceuticals (RIGL) Story Is Shifting After Q3 And 2025 Guidance - Yahoo Finance |
| 2021-05-21 | -2.0% | legal | SEC EDGAR | RIGL 8-K: 5.02 and 5.07 (SEC Filing) |
| 2024-01-08 | -2.0% | legal | SEC EDGAR | RIGL 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-05-23 | -1.9% | legal | SEC EDGAR | RIGL 8-K: 5.02 and 5.07 (SEC Filing) |
| 2026-02-10 | +1.8% | news | Seeking Alpha | Top Quant rated bullish small cap stocks among companies with high short interest |
| 2023-02-03 | -1.7% | legal | SEC EDGAR | RIGL 8-K: 5.02 (SEC Filing) |
| 2026-01-16 | -1.7% | earnings | Yahoo Finance | Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? - Yahoo Finance |
| 2026-02-03 | -1.6% | legal | SEC EDGAR | RIGL 8-K: 5.02 (SEC Filing) |
| 2025-12-10 | -1.6% | legal | SEC EDGAR | RIGL 8-K: 8.01 and (SEC Filing) |
| 2023-05-02 | -1.6% | legal | SEC EDGAR | RIGL 8-K: 2.02 and (SEC Filing) |
| 2025-03-10 | -1.5% | legal | SEC EDGAR | RIGL 8-K: 5.02 (SEC Filing) |
| 2022-11-01 | -1.2% | legal | SEC EDGAR | RIGL 8-K: 8.01 and (SEC Filing) |
| 2022-01-10 | +0.8% | legal | SEC EDGAR | RIGL 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-11-25 | +0.7% | news | Seeking Alpha | Rigel Pharmaceuticals: Behind The Huge Rally |
| 2025-09-26 | -0.7% | news | Seeking Alpha | Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion |
| 2025-09-26 | -0.7% | news | Yahoo Finance | Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance |
| 2025-11-26 | +0.6% | earnings | Seeking Alpha | Rigel Pharma: Q3 Earnings Showcase Robust Growth |
| 2026-02-24 | -0.5% | earnings | Finviz | Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? - Finviz |
| 2026-03-27 | -0.4% | news | Insider Monkey | Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It’s Doing Better Than People Realize” |
| 2026-03-27 | -0.4% | news | Zacks | Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? |
| 2021-05-14 | +0.4% | legal | SEC EDGAR | RIGL 8-K: 5.02 (SEC Filing) |
| 2026-03-16 | +0.4% | news | Motley Fool | Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data |
| 2024-09-03 | +0.3% | legal | SEC EDGAR | RIGL 8-K: 1.01 (SEC Filing) |
| 2024-09-19 | -0.3% | legal | SEC EDGAR | RIGL 8-K: 5.02 (SEC Filing) |
| 2026-01-14 | -0.3% | earnings | Yahoo Finance | A Look At Rigel Pharmaceuticals (RIGL) Valuation After Issuing 2026 Revenue Guidance - Yahoo Finance |
| 2026-04-24 | — | news | Zacks | Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock? |
| 2026-04-24 | — | news | TradingView | Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock? - TradingView |